In brief. Coenzyme Q10 (CoQ10) is a fat-soluble molecule involved in the mitochondrial respiratory chain. Régénère™ provides 30 mg/day of CoQ10 as ubiquinone. A randomized, double-blind, placebo-controlled trial published in 2017 studied 50 or 150 mg/day for 12 weeks in 33 adults using the proprietary water-soluble formulation Q10Vital®. Some wrinkle, microrelief and skin-smoothness parameters improved, while hydration and dermal thickness did not show a significant effect. Eclo evidence rating: published human data on oral CoQ10, but not directly transferable to 30 mg of ubiquinone in Régénère™ because the dose and formulation differ.

CoQ10 at a glance

What is CoQ10’s biological role?

CoQ10 participates in electron transfer within mitochondria, a process associated with ATP production. It also has redox properties. This biochemical role is well established, but a cellular mechanism alone does not demonstrate that supplementation at a given dose improves skin.

Ubiquinone and ubiquinol: what is the difference?

Ubiquinone is an oxidized form and ubiquinol a reduced form of CoQ10. The body can convert one into the other. Bioavailability also depends on the delivery vehicle, formulation and context of intake. The name of the form alone therefore does not predict the clinical effect.

What did the trial in 33 adults show?

The study followed 33 adults for 12 weeks using 50 or 150 mg/day of a proprietary water-soluble form, Q10Vital®. The authors report a limitation of seasonal deterioration in viscoelasticity, a reduction in certain wrinkles and microrelief lines, and an improvement in skin smoothness.

However, they did not observe a significant change in hydration or dermal thickness. Keeping these neutral findings matters: a study that is positive on some endpoints does not demonstrate an effect on every skin parameter.

Why does this trial not prove an effect of Régénère™?

Régénère™ provides 30 mg of ubiquinone, while the trial used 50 or 150 mg of Q10Vital®. Both dose and formulation differ. Copying the study findings onto Régénère™ would therefore be an extrapolation.

Does more CoQ10 mean more effect?

Not automatically. The presence of two doses in a trial does not demonstrate a linear relationship in which “more dose = proportionally more effect”. Dose-response must be shown endpoint by endpoint.

Is there an authorized EU health claim for CoQ10?

CoQ10 does not have, in the European reference list used here, an authorized health claim comparable to those available for certain vitamins and minerals. Eclo therefore remains descriptive about identity, dose and literature rather than turning a mitochondrial role into a therapeutic or beauty promise.

What we know — and what it does not allow us to conclude

• Documented: CoQ10 participates in the mitochondrial respiratory chain.
• Human study: a 12-week RCT studied 50 and 150 mg/day of Q10Vital®.
• Useful neutral finding: no significant effect on hydration or dermal thickness.
• Do not extrapolate: Q10Vital® 50/150 mg is not equivalent to 30 mg ubiquinone.
• Do not extrapolate: this study is not a study of Régénère™.

Frequently asked questions

Has oral CoQ10 been studied for skin?

Yes. But human data remain limited and the studied formulations do not necessarily match Eclo’s.

Did the 2017 trial improve hydration?

Not significantly. The authors did not observe a significant effect on hydration or dermal thickness.

Is 150 mg three times as effective as 50 mg?

That cannot be concluded. A dose-response relationship is not automatically proportional.

Does 30 mg in Régénère™ reproduce the trial?

No. Dose and formulation differ.

Sources

• [Publication] Žmitek et al. — oral CoQ10 and skin parameters, BioFactors, 2017

Read next

How to read a clinical study · Understanding doses · Régénère™

Method note: Eclo retains negative or neutral findings and does not transfer results from a proprietary formulation to a different dose or formulation.

Last scientific review: 27 August 2026.